Suberoylanilide-d5 Hydroxamic Acid

• CAT Number: R007036
• CAS Number: 1132749-48-4
• Molecular Formula: C14H20N2O3
• Molecular Weight: 269.356
• Purity: ≥95%
• Synonyms: SAHA-d5; N-Hydroxy-N’-phenyl-d5-octanediamide; Zolinza-d5; Vorinostat-d5
• Target: Epigenetics
• Storage: -20°C
• IUPAC Name: N/'-hydroxy-N-(2,3,4,5,6-pentadeuteriophenyl)octanediamide
• InChI: InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)/i3D,4D,5D,8D,9D
• InChIKey: WAEXFXRVDQXREF-YQYLVRRTSA-N
• SMILES: [2H]C1=C(C(=C(C(=C1[2H])[2H])NC(=O)CCCCCCC(=O)NO)[2H])[2H]

Suberoylanilide-d5 Hydroxamic Acid is a deuterated form of suberoylanilide hydroxamic acid (SAHA), commonly known as vorinostat, a potent histone deacetylase (HDAC) inhibitor used in cancer therapy. This compound features five deuterium atoms, which enhance its stability and enable precise tracking in pharmacokinetic and metabolic studies. Suberoylanilide-d5 Hydroxamic Acid is particularly valuable in research focused on epigenetic modulation, as it helps to study the inhibition of HDACs, leading to altered gene expression and apoptosis in cancer cells. It is also used in isotope-dilution mass spectrometry as an internal standard, ensuring accurate and reproducible results in analytical assays. This isotopically labeled compound is a critical tool in the development and optimization of HDAC inhibitors for therapeutic applications.